Table 6

Sequential WOMAC C Scores – Physical Function

Group

Baseline

Week 1

Week 2

Week 4

Week 6

Week 8

Placebo

36.4 ± 3.9

37.0 ± 4.3

35.0 ± 4.4

32.0 ± 4.3

29.5 ± 4.5

26.6 ± 4.6 **

A

38.4 ± 4.9

32.4 ± 5.3

31.0 ± 5.1 **

26.1 ± 4.6 ***

26.3 ± 4.6 ***

23.1 ± 4.6 ***

B

34.7 ± 4.2

31.3 ± 4.4 *

28.7 ± 4.4 **

24.5 ± 3.8 ***

22.8 ± 3.9 ***

21.3 ± 2.9 ***

C

32.8 ± 4.3

31.1 ± 4.0

29.1 ± 4.0 *

24.3 ± 3.4 ***

21.7 ± 3.5 ***

19.7 ± 3.4 ***

Data expressed as mean ± sem. Group A = High dose sierrasil (n = 20), Group B = Low dose sierrasil (n = 21), Group C = Low dose sierrasil + cat's claw extract (n = 25), placebo n = 22. All groups displayed a significant change over the 8 weeks of the study (p < 0.001, ANOVA). Using the Wilcoxan Matched-Pairs Signed-Rank test the following descriptors reflect statistical significance from baseline; * p < 0.05, ** p < 0.01, *** p < 0.001.

Miller et al. Journal of Inflammation 2005 2:11   doi:10.1186/1476-9255-2-11